blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2949740

EP2949740 - NOVEL ORGANOLEPTIC COMPOUND [Right-click to bookmark this link]
Former [2015/49]Novel organoleptic compound
[2016/33]
StatusNo opposition filed within time limit
Status updated on  13.10.2017
Database last updated on 24.08.2024
FormerThe patent has been granted
Status updated on  04.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
International Flavors & Fragrances Inc.
521 West 57th Street
New York, NY 10019 / US
[2015/49]
Inventor(s)01 / Yun, Heedong
8 Demott Street
Tenafly, NJ 07670 / US
 [2015/49]
Representative(s)Lawrence, John
Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
[2015/49]
Application number, filing date15164982.924.04.2015
[2015/49]
Priority number, dateUS20141428760127.05.2014         Original published format: US201414287601
[2015/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2949740
Date:02.12.2015
Language:EN
[2015/49]
Type: B1 Patent specification 
No.:EP2949740
Date:07.12.2016
Language:EN
[2016/49]
Search report(s)(Supplementary) European search report - dispatched on:EP19.10.2015
ClassificationIPC:C11B9/00, C07C33/14
[2016/32]
CPC:
C11B9/0034 (EP,CN,US); C07C33/14 (EP,CN,US); C11D3/50 (EP,US);
C07C2601/16 (EP,US); C07C403/08 (US)
Former IPC [2015/50]C07C403/08, C11D3/50, C07C33/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/26]
Former [2015/49]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:NEUARTIGE ORGANOLEPTISCHE VERBINDUNG[2015/49]
English:NOVEL ORGANOLEPTIC COMPOUND[2016/33]
French:NOUVEAU COMPOSÉ ORGANOLEPTIQUE[2015/49]
Former [2015/49]Novel organoleptic compound
Examination procedure23.05.2016Examination requested  [2016/26]
21.07.2016Communication of intention to grant the patent
21.10.2016Fee for grant paid
21.10.2016Fee for publishing/printing paid
21.10.2016Receipt of the translation of the claim(s)
Opposition(s)08.09.2017No opposition filed within time limit [2017/46]
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.04.2015
AL07.12.2016
AT07.12.2016
BE07.12.2016
CY07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
MK07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
TR07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
IE24.04.2017
LU24.04.2017
MT24.04.2017
[2020/34]
Former [2020/15]HU24.04.2015
AT07.12.2016
BE07.12.2016
CY07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
MK07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
TR07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
IE24.04.2017
LU24.04.2017
MT24.04.2017
Former [2019/52]HU24.04.2015
AT07.12.2016
BE07.12.2016
CY07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
MK07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
IE24.04.2017
LU24.04.2017
MT24.04.2017
Former [2019/48]HU24.04.2015
AT07.12.2016
BE07.12.2016
CY07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
IE24.04.2017
LU24.04.2017
MT24.04.2017
Former [2019/31]HU24.04.2015
AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
IE24.04.2017
LU24.04.2017
MT24.04.2017
Former [2018/43]AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
IE24.04.2017
LU24.04.2017
MT24.04.2017
Former [2018/23]AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
IE24.04.2017
LU24.04.2017
Former [2018/14]AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
LU24.04.2017
Former [2018/06]AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
MC07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2017/52]AT07.12.2016
BE07.12.2016
CZ07.12.2016
DK07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SI07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2017/42]AT07.12.2016
BE07.12.2016
CZ07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
IT07.12.2016
LT07.12.2016
LV07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SK07.12.2016
SM07.12.2016
BG07.03.2017
NO07.03.2017
GR08.03.2017
IS07.04.2017
PT07.04.2017
Former [2017/36]BE07.12.2016
CZ07.12.2016
EE07.12.2016
FI07.12.2016
HR07.12.2016
LT07.12.2016
LV07.12.2016
PL07.12.2016
RO07.12.2016
RS07.12.2016
SE07.12.2016
SK07.12.2016
NO07.03.2017
GR08.03.2017
IS07.04.2017
Former [2017/34]CZ07.12.2016
FI07.12.2016
HR07.12.2016
LT07.12.2016
LV07.12.2016
RS07.12.2016
SE07.12.2016
NO07.03.2017
GR08.03.2017
Former [2017/28]FI07.12.2016
HR07.12.2016
LT07.12.2016
LV07.12.2016
RS07.12.2016
SE07.12.2016
NO07.03.2017
GR08.03.2017
Former [2017/12]LV07.12.2016
Documents cited:Search[A]GB1476720  (GIVAUDAN & CIE SA) [A] 1-13 * example IV; claims 1-24 *;
 [A]EP0183970  (BASF AG [DE]) [A] 1-13 * page 8; example 1; claims 1-4 *;
 [A]US2003220507  (MACMILLAN DAVID W C [US], et al) [A] 1 * example 5; table 3 *;
 [T]US9051532  (YUN HEEDONG [US]) [T] 1-13* claims 1-9 *;
 [A]  - GUIOTTO, A. ET AL, "Synthesis and attractiveness for Ceratitis capitata Wied. males of .DELTA.3-cyclohexenylalkylcarbinol acetates. IV", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1980:490132, URL: STN, XP002744680 [A] 1 * abstract *
ExaminationUS4283576
by applicantUS4195099
 US4534891
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.